Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy
Authors:
- 21 May 2014
- journal article
- review article
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 101 (8) , 925-938
Abstract
Background Wide variability in breast cancer, between patients and within each individual neoplasm, adds confounding complexity to the treatment of the disease. In clinical practice, hormone receptor status has been used to classify breast tumours and to guide treatment. Modern classification systems should take the wide tumour heterogeneity into account to improve patient outcome. Methods This article reviews the identification of the intrinsic molecular subtypes of breast cancer, their prognostic and therapeutic implications, and the impact of tumour heterogeneity on cancer progression and treatment. The possibility of functionally addressing tumour‐specific characteristics in in vivo models to inform decisions for precision therapies is also discussed. Results Despite the robust breast tumour classification system provided by gene expression profiling, heterogeneity is also evident within these molecular portraits. A complicating factor in breast cancer classification is the process of selective clonality within developing neoplasms. Phenotypically and functionally distinct clones representing the intratumour heterogeneity might confuse molecular classification. Molecular portraits of the heterogeneous primary tumour might not necessarily reflect the subclone of cancer cells that causes the disease to relapse. Studies of reciprocal relationships between cancer cell subpopulations within developing tumours are therefore needed, and are possible only in genetically engineered mouse models or patient‐derived xenograft models, in which the treatment‐induced selection pressure on individual cell clones can be mimicked. Conclusion In the future, more refined classifications, based on integration of information at several molecular levels, are required to improve treatment guidelines. Large‐scale translational research efforts paved the way for identification of the intrinsic subtypes, and are still fundamental for ensuring future progress in cancer care.Keywords
This publication has 114 references indexed in Scilit:
- Whole-genome analysis informs breast cancer response to aromatase inhibitionNature, 2012
- The Life History of 21 Breast CancersCell, 2012
- Tumorigenic Cells Are Common in Mouse MPNSTs but Their Frequency Depends upon Tumor Genotype and Assay ConditionsCancer Cell, 2012
- Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenograftsBreast Cancer Research and Treatment, 2011
- The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastasesCancer, 2010
- Deconstructing the molecular portraits of breast cancerMolecular Oncology, 2010
- Genomic instability in breast cancer: Pathogenesis and clinical implicationsMolecular Oncology, 2010
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem CellsCell, 2008
- ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical OutcomeCell Stem Cell, 2007
- High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analysesInternational Journal of Cancer, 2005